HIGHLIGHTS
- who: Yuchen Wan from the Shanghai General Hospital, China Fudan University, China have published the article: Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review, in the Journal: (JOURNAL) of September/15,/2020
SUMMARY
Multiple primary malignancies (MPMs) were firstly described by Billroth and defined as the concurrence of two or more different neoplasms in the same individual. With the evolution in the diagnosis and treatment of cancer, a higher proportion of surviving patients with cancer is at a greater risk of developing a second . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.